Kornimate/medical-research-clean huggingface dataset:
nicotine treatment for pulmonary sarcoidosis: a clinical trial pilot study

Conditions: Sarcoidosis

Summary: the purpose of this study is to determine if nicotine treatment is beneficial for the treatment of sarcoidosis. sarcoidosis is a disease of unknown cause that leads to inflammation. this disease affects your body's organs.

participants will be randomly divided into two groups. one group will receive a nicotine patch to use for approximately 7 months; the other group will receive placebo for nicotine patches to use for the same time period. both groups will be contacted weekly by phone for the first 3 weeks then monthly for the duration of the study to monitor for any side effects. the following information and samples will be collected: questionnaires medical history spirometry ct scans physical exam blood samples for nicotine and nicotine metabolites

Eligibility criteria:
inclusion criteria: * adult male and female subjects ≥ 18 to ≤ 75 years of age will be screened for eligibility. * eligible adult patients will have histologically proven sarcoidosis, diagnosed at least 6 months before screening, evidence of parenchymal disease on chest radiograph, an fvc between 50% and 85% of the predicted value, and a medical research council dyspnea score (47) of at least grade 1. * patients must have been treated with at least 10 mg/day of prednisone or equivalent or one or more immunomodulating agents (hydroxychloroquine, methotrexate, azathioprine, leflunomide) for \>3 months before screening. * doses of these medications must be stable for at least 1 month before study entry. * during the study, background medication regimen and doses are to remain stable. exclusion criteria: * active tobacco smoking or use of smokeless tobacco products containing nicotine, * active cardiac or central nervous system disease, * history of adverse reaction to nicotine or nicotine-containing products, * patients with extensive irreversible pulmonary fibrosis (based upon lung biopsy or high resolution ct scan criterion) or inability to provide consent. the subject will be excluded if they have a smoking history of greater than 20 pack years, or a diagnosis of other significant respiratory disorder other, than sarcoidosis that, in the opinion of the investigator, would complicate the evaluation of response to treatment; or, history of substance abuse (drugs or alcohol) within 3 years prior to screening or other circumstances (e.g., psychiatric disease) that could interfere with the subject's adherence to protocol requirements or increase their risk of drug (nicotine) dependence.
assessment of asymptomatic heart disease in children with hiv

Conditions: HIV Infections

Summary: the purpose of this study is to perform cardiac evaluation in hiv-1 (predominantly clade c)infected children by history, physical examination, echocardiogram and plasma n-terminal pro-b-type natriuretic peptide (n-bnp)measurement in order to determine asymptomatic abnormalities.

human immunodeficiency virus (hiv) infection affects nearly 40 million adults and children worldwide. recently introduced new antiviral drugs have significantly improved survival of patients with hiv infection. as mortality declines, morbidity becomes a concern. heart disease is present in 20% of children and adults with hiv. the cardiac diseases include left ventricular dysfunction, hypertrophy and dilation, pericardial effusion and intracardiac masses. cardiac disease is an independent risk factor for death in these children. the reported two-year survival of children with congestive heart failure is zero compared to 17% when no heart failure is present. it is thus indicated to perform periodic cardiac examinations in these patients, and early recognition of cardiac disease is paramount. in addition to the traditional tools to assess cardiac status which include history, physical examination, ecg, chest x-ray and echocardiography, we propose to check biochemical markers. brain natriuretic peptide has been shown to be a very sensitive marker for symptomatic and asymptomatic cardiac dysfunction, prognosis, severity of the disease and response to therapy in adults. troponin-t is a very good marker for cardiac ischemia. recently, we have found troponin-t to be a good marker for acute cardiac insult in infants and children. the aim of this study is to perform screening of children with hiv predominantly clade c for cardiac disease using the above mentioned means.

Eligibility criteria:
inclusion criteria: * infants and children congenitally infected with hiv-1

Keywords: hiv aids troponin natriuretic peptide heart failure heart disease children hiv pediatric aids pediatric
effectiveness of metal protheses covered in "diabolo" in treatment of necrosis of origin pancreatic: trial "diabolopig"

Conditions: Pancreatic Diseases

Summary: endoscopic treatment of pancreatic necrosis complicated by trans digestive track (duodenal or gastric) has become a standard technique validated. the rate of high technical and clinical success (76 to 91% in 3 months) and the lower morbidity in the literature explains that validation. however this treatment is done at the cost of a higher median number of treatment sessions (4-5) explaining prolonged hospitalization, delays in rehabilitation and potentially high costs. the constant improvement of therapeutic endoscopy equipment was allowed to see the advent of metal prosthesis completely covered by a membrane allowing them endoscopic extraction with ease. it has thus been recently developed short prostheses, of large diameter (up to 15/16 mm), with broad flange (or stent "diabolo") to be considered for use in the drainage of digestive peri collections. few studies respectively determined the effectiveness of this type of prosthesis in the drainage of peri digestive collections under echo endoscopy and treatment of necrosis of pancreatic origin. the purpose of this work is to evaluate multicenter prospective clinical and technical efficiency of laying completely covered stent "diabolo" in echo endoscopy for the treatment of necrosis of pancreatic origin.


Eligibility criteria:
inclusion criteria: presence of peri gastric or duodenal collection type wopn to imaging according to the atlanta criteria (banks gut 2013) with predominantly solid component (\> 50%) for imaging, requiring necrosectomy for: * pain and / or, * necrosis infection (positive necrosis culture, gas bubble presence in the collection on imaging, persistent sepsis or deterioration of the patient's condition despite optimal reanimation support without documented infection) and / or, * high occlusion (vomiting, food intolerance and gastric stasis at imaging) exclusion criteria: * severe coagulation disorders or hemostasis
development of auditory skills in young deaf children with bilateral cochlear implants

Conditions: Deafness

Summary: the primary objective to this study is to describe the auditory development and performance of young deaf children who receive bilateral implants during the first two years following device activation.

the primary purpose of this study is to track patient outcomes for bilateral cochlear implant recipients in a cohort of children, ages 12 to 36 months at time of surgery, who receive two implants in the same operation or in two different surgeries with the initial fitting of the devices separated by no more than six months. acquisition of auditory milestones and speech recognition skills, which underpin the development of spoken language, will be assessed on a battery of outcome measures typically used to quantify implant benefits. in addition, global quality of life and communicative performance will be assessed by parental proxy. performance will be tracked after 3, 6, 12, 18, and 24 months of device use. the study also will identify variables that may predict the degree of bilateral implant benefit in young children (e.g., age at implant, pre-implant hearing thresholds, communication mode, family socioeconomic status, post-implant aided thresholds, simultaneous vs. staged placement of devices).

Eligibility criteria:
inclusion criteria: * profound bilateral hearing loss (pta\>= 90db hl) * have independently elected to undergo bilateral implantation of advanced bionics hiresolution bionic ear system and meet all the eligibility criteria for this device as described in the product labeling. * age at implant: 12-36 months * negligible benefit from hearing aids, defined as failure to reach developmentally appropriate milestones on it-mais * no previous cochlear implant use * normal/patent cochlea with no more than a mild "partitioning" defect in either ear * english as the primary language spoken in the home * parental willingness to follow study protocol exclusion criteria: * deafness secondary to meningitis * presence of other conditions that could affect performance on outcome measures or otherwise confound or interfere with study participation of outcomes measures.

Keywords: deafness hearing loss cochlear implants advanced bionics hiresolution bionic ear system
construction of a database for ttp

Conditions: TTP - Thrombotic Thrombocytopenic Purpura

Summary: information about patients was collected by reviewing the hitech case system and telephone and outpatient follow-up, and the case database was constructed by epidata software. the sample size is expected to be 200 cases, the participating hospital is the first affiliated hospital of soochow university, and the study time frame is from oct 20, 2022, to oct 20, 2027. the observation indexes of the study include the basic information of patients' age and gender and the clinical related data of thrombotic thrombocytopenic purpura.


Eligibility criteria:
inclusion criteria: - subjects diagnosed with severe adamts13 deficiency, defined as adamts13 activity \<10%, documented in the patient's medical history or at screening. exclusion criteria: - the investigator considers the subject unable or unwilling to cooperate with the study procedures.
two-way interaction between alisporivir and edp239

Conditions: Hepatitis C Virus

Summary: the purpose of part 1 is to inform dose selection for use of alisporivir and edp239 in combination and obtain initial safety data for co-administration of alisporivir and edp239 to support future treatment studies in patients. the purpose of part 2 is to inform the drug-drug interaction potential of edp239 more broadly and possibly facilitate the interpretation of lower than expected alisporivir concentrations in part 1, if observed.


Eligibility criteria:
inclusion criteria: * male or female subjects 18 to 55 years of age * body weight at least 50 kg exclusion criteria: * women of child bearing potential * tobacco use * history or evidence of any inherited bilirubin disease or disorder, including not not necessarily limited to dubin-johnson syndrome, gilbert's syndrome, and rotor syndrome

Keywords: hepatitis c virus, viral, antiviral, infection, infectious disease, alisporivir, edp239, deb025
evaluating the efficacy of annual chtc retesting among male couples at high risk of hiv infection

Conditions: HIV Infections

Summary: this randomized controlled trial evaluates the efficacy of couples hiv testing and counseling retesting. eligible couples previously enrolled in nct05000866 are invited to participate. those who do are randomized to either couples hiv testing and counseling (chtc) retesting or an individual hiv testing control. follow-ups occur 3 and 6 months post intervention.

the purpose of this study is to evaluate the benefits associated with couples hiv testing and counseling (chtc) resting. after their 12-month follow-up, those participants who remain in the same relationship they were in at the time of their baseline will be offered the opportunity to continue in the components proposed in this revision. those who consent will be randomized to either complete a second session of chtc or to a comparison condition in which both partners receive a routine individual hiv test. hiv positive partners in serodiscordant couples randomized to the control condition will receive information about anti-retroviral treatment adherence and u=u (undetectable = untransmissible). given potential attrition and rates of relationship dissolution, we anticipate randomizing 200 couples (80% of the original sample). follow-up assessments will be conducted 3 and 6 months after retesting (15 and 18 months after the participants' original baseline appointment).

Eligibility criteria:
inclusion: 1. enrolled previously in the parent study da050508 (nct05000866). 2. in a relationship with the same main partner with whom they completed the baseline intervention session. 3. both partners in the couple must consent to continue with activities specified in this revision. 4. completion of the 12-month assessment associated with participation in the parent study prior to consenting to participate in activities specified under this revision. exclusion: any of the following at the 12-month follow-up: 1. serious psychiatric symptoms; 2. current suicidal/homicidal ideation; 3. gross cognitive impairment 4. a history of severe physical or sexual intimate partner violence (ipv) victimization in the current relationship.
treatment for first-episode schizophrenia

Conditions: Schizophrenia

Summary: this 3-year study will determine if the antipsychotic medications olanzapine (zyprexa®) and risperidone (risperdal®) can help patients with first-episode schizophrenia.

the goal of the study is to prevent morbidity in first-episode schizophrenia using second-generation antipsychotic drugs: olanzapine, risperidone. long-term studies of first-episode schizophrenia patients have clearly indicated excellent initial responsiveness of positive psychotic symptoms to treatment with conventional antipsychotic medications. however, in the years immediately following this initial good response, morbidity increases. relapses, often multiple ones, are the rule and are usually precipitated by medication noncompliance. there is some evidence that the second-generation antipsychotic drugs may have superior efficacy in terms of these outcome domains. however, these newer agents have been studied primarily in chronic and/or treatment-resistant patient samples and there are virtually no long-term studies or studies comparing the new drugs with one another. first episode patients are randomly assigned to treatment with olanzapine or risperidone for 3 years. outcome measures for the initial episode include psychopathology (positive, negative, and affective symptoms), side effects, neurocognition (executive function, memory, and attention), social and occupational function and service utilization. the effects on long-term course are measured in terms of frequency and timing of relapses, level of recovery from subsequent episodes and prospectively assessed course of psychopathology, neurocognitive function, social/vocational function, and service utilization. for information on a related study, please follow this link: http://clinicaltrials.gov/show/nct00320671

Eligibility criteria:
inclusion criteria: * first episode schizophrenia, schizophreniform disorder or schizoaffective disorder exclusion criteria: * prior treatment with antipsychotic medications.

Keywords: adolescence adult antipsychotic agents female human male olanzapine risperidone schizophrenia antipsychotic agents -- *therapeutic use olanzapine -- *therapeutic use risperidone -- *therapeutic use schizophrenia -- *drug therapy
relevance of the peripheral cholinesterase-activity on neurocognitive dysfunctions in surgical patients

Conditions: Postoperative Delirium

Summary: in this prospective, multicenter observational study the investigators capture the perioperative course of peripheral cholinesterase activity. the focus is the perioperative inflammation causing postoperative delirium. therefore we measure the activity of acetylcholine-esterase and butyrylcholine-esterase in whole blood of adults in the perioperative context. early postoperative delirium will be detected by nu-desc in the recovery room or the postanaesthesia-care-unit. the course of the peripheral cholinesterase activity will be compared with the incidence of postoperative delirium and other clinical dysfunctions. we follow up the patients for up to five years regarding delirum, comorbidities and mortality data.


Eligibility criteria:
inclusion criteria: * male and female patients with age 18 years and above scheduled for surgery with planned stay in recovery room or postanesthesia-care-unit * offered patient information and written informed consent * in-hospital stay for at least 24 hours exclusion criteria: * patients with known pseudocholinesterase deficiency * participation in prospective intervention studies during the study period * analphabetism * unability of german and english language use * anacusis or hypoacusis with hearing aid device, amaurosis * lacking willingness to save and hand out data within the study * accommodation in an institution due to an official or judicial order * coworker of the clinic (study center)

Keywords: nursing delirium screening scale, acetylcholinesterase activity
acute-remotion: remotion in acute psychiatric care

Conditions: Mental Disorder

Summary: this study aims to examine remotion, an internet-based intervention aimed at reducing symptom severity and improving emotion regulation in an acute psychiatric inpatient care setting. remotion is currently being studied in an outpatient psychotherapy setting. this study aims to investigate feasibility and first effects of this intervention in inpatient psychiatric care.


Eligibility criteria:
inclusion criteria: * 18 or older * in acute inpatient care * with internet access * informed consent given exclusion criteria: * current participation in another specific emotion regulation intervention group * current or history of psychotic disorders, bipolar disorder, mental retardation or organic mental disorders * acute suicidality * insufficient mastery of german language
glycaemic response to a liquid meal tolerance test

Conditions: Glycaemic Index; Glycaemic Response

Summary: the purpose of this study is to assess whether added food ingredient(s) affect glycaemic responses to a liquid meal tolerance test (lmtt).


Eligibility criteria:
inclusion criteria: 1. male or female (not less than 40% male) 2. aged 18 - 55 years 3. non smokers 4. have a body mass index between 18.5 to 29.99 kg/m2 5. healthy, non-diabetic, no gastric bypass surgery 6. not allergic to dairy, or soy 7. have a fasting plasma glucose (finger-stick) \<100 mg/dl (\<5.5 mmol/l) 8. willing and able to provide written informed consent
dexmedetomidine influence on the level of perioperative blood glucose and insulin of elderly diabetes patients

Conditions: Perioperative Blood Glucose and Insulin

Summary: dexmedetomidine is a kind of high selectivity alpha 2 agonists adrenaline, can inhibit the activity of sympathetic nerve, alleviate pain,and improve cardiovascular stability in the operation period. dexmedetomidine have influence on perioperative stress response and immune function,but it is not clear.


Eligibility criteria:
inclusion criteria: * aged 60 to 80 years old; * type 2 diabetes; * not use insulin treatment; * onging general anesthesia surgery; * surgery time 1-3 hours exclusion criteria: * asa classification \> class ii; * hypertension; * serious central nervous system diseases (acute stroke, uncontrolled seizures, -severe dementia); * unstable angina and acute myocardial infarction; * allergy to investigational drug; * hepatic and renal dysfunction

Keywords: dexmedetomidine perioperative blood glucose and insulin
effectiveness of sodium fusidate ointment compared to petrolatum for wound healing following cauterization

Conditions: Seborrheic Keratosis; Acrochordon

Summary: a double-blind within person randomized controlled trial study was conducted on 90 wounds in 22 subjects. all wounds were randomized to receive either sodium fusidate ointment or petrolatum following cauterization.

all eligible participants were randomized to be applied sodium fusidate ointment (intervention) or white petrolatum (control) on the lesions on their face with 1:1 ratio. allocation sequence was generated by a statistician with a computer and it was concealed from the researchers and participants. the ointment was prepared and packaged by a pharmacist. each pot was numbered in accordance with the allocation sequence. electrosurgery was carried out using ellman® surgitron. prior to the cauterization, we performed infiltration anesthesia around the lesion with pehacain® (containing 20 mg of lidocaine and 0.0125 mg/ml epinephrine). the tissue was cleaned using sterile gauze or a cotton swab that had been moistened with 0.9% nacl. following electrosurgery, sodium fusidate ointment or petrolatum was applied to the wound according to the allocation sequence. the patient also received a wound care instruction sheet. this sheet contained information on how to wash the face or body properly, how to apply the ointment properly, what to avoid after procedure (rubbing the wound excessively, use make up, sweating excessively, and use other topical agents on the wound), and follow-up instructions (on the 3rd, 7th, and 14th day). each subject was given two or four pots of ointment that should be applied twice daily on the wound. wound monitoring, which includes erythema, edema, crusting, re-epithelialization, total wound healing score, pus, and subjective symptoms was performed on the 3rd, 7th, and 14th day. erythema scores was also monitored immediately after electrosurgery. monitoring can be done 1 day earlier or later than schedule in some cases since the wound healing phase is expected still the same. clinical grading of each site was carried out using a 5-point analog scale for erythema, edema, crusting, re-epithelialization, and total wound healing score.

Eligibility criteria:
inclusion criteria: * age over 20 years * clinically diagnosed with seborrheic keratosis or acrochordon * having minimum of two lesions and maximum of four lesions with diameter of 4-10 mm on face or neck and minimum distance between lesions of 5 cm * providing consent to participate into the study exclusion criteria: * a skin bacterial infection on the other parts of body's skin * benign tumor lesions with inflammation or secondary infection * history of antibiotics use in the last 2 weeks or long-acting penicillin injections within the past 1 month * history of corticosteroids and immunosuppressants use in the past 2 weeks * using a pacemaker * infected with coronavirus disease 2019 (covid-19).

Keywords: wound healing cauterization sodium fusidate ointment petrolatum
a study on breast cancer patient care using chatbot and video education for radiation therapy (brave)

Conditions: Breast Neoplasms

Summary: this randomized trial explored whether digital media (videos and chatbots) used for patient education could more effectively reduce anxiety in breast cancer patients during radiation therapy, compared to traditional paper-based methods. post-surgery breast cancer patients scheduled for radiation therapy were assigned to groups receiving treatment information through different media combinations. the study aimed to assess whether these modern tools more effectively ease anxiety, thus potentially improving patient compliance and treatment experience.

this study evaluates the impact of patient management and information provision using educational videos and chatbots on patient experience, satisfaction, and patient psychology in the breast cancer radiation treatment process. the experiment is designed as (2 (with or without using chatbot) x 2 (with or without using video) to distinguish groups. there is no separate treatment intervention in addition to use chatbot and video utilization.

Eligibility criteria:
inclusion criteria: 1. a breast cancer patient scheduled for radiation therapy after radical surgery. 2. subjects must have the cognitive ability to use smartphone. 3. age ≥ 20 year old exclusion criteria: 1. patients with visual or auditory impairment. 2. subjects do not consent to participate in this study. 3. pregnancy, fetus, newborn, underage 4. age ≥ 75 year old